TickerGuard
Buy Day today: Neutral (59) Mixed market breadth · major macro event coming up
TAK

Takeda Pharmaceutical Co Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

17.40$ -0.1% vs. previous close Closing price · As of: Aug 13, 2026

Statements

Income Statement

Takeda Pharmaceutical Co Ltd (TAK) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 1,219,900 million JPY. Tick rows to compare them in a chart.

All figures in millions of JPY.

Tick rows to compare them in a chart (up to 4)

Income Statement TAK
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
1,043,089 1,111,186 1,050,869 1,207,990 1,176,038 1,144,124 1,053,400 1,106,685 1,112,796 1,213,211 1,114,649 1,219,900 4,660,556
343,582 379,481 387,328 386,954 394,311 416,874 382,100 384,675 380,061 552,866 570,839 406,676 1,910,441
699,507 731,705 663,541 821,036 781,727 727,250 671,300 722,010 732,735 660,346 543,810 813,224 2,750,115
183,946 187,381 195,856 168,463 175,564 170,193 216,000 143,891 161,482 178,394 198,908 167,395 706,180
252,952 267,520 285,234 270,030 268,282 270,588 295,866 255,885 253,551 282,783 291,996 286,513 1,114,843
748,850 626,791 673,610 654,707 597,480 660,308 746,200 537,444 663,740 466,282 496,269 611,807 2,238,098
-49,341 104,914 -10,069 166,329 184,247 66,942 -74,900 184,566 68,995 194,063 47,542 201,417 512,017
401 66,568 318 59,691 68,454 207 330 107,158 83,138 125,859 44,451 63,845 317,293
-95,980 61,260 -47,522 136,604 119,372 26,407 -107,300 150,630 28,174 136,281 -53,443 162,718 273,730
-48,009 -44,496 -44,528 41,304 27,266 2,572 -4,200 26,351 39,903 30,675 -28,740 49,462 91,299
-48,030 105,720 -3,018 95,248 92,046 23,789 -103,200 124,243 -11,802 105,510 -24,766 113,197 182,139
202,284 257,026 259,235 388,515 380,278 193,007 181,269 439,424 316,467 456,220 157,888 337,491 1,268,066

LTM = last twelve months (sum of the four most recent quarters).

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?